Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines

TKI resistance remains a major impediment to successful treatment of CML. In this study, we investigated the emerging modes of ponatinib resistance in TKI-naïve and dasatinib resistant BCR-ABL1+ cell lines. To investigate potential resistance mechanisms, ponatinib resistance was generated in BCR-ABL...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Liu, Kok, Chung Hoow, Saunders, Verity Ann, Wang, Jueqiong, McLean, Jennifer Anne, Hughes, Timothy Peter, White, Deborah Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205183/
https://www.ncbi.nlm.nih.gov/pubmed/30410673
http://dx.doi.org/10.18632/oncotarget.26187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205183/
https://www.ncbi.nlm.nih.gov/pubmed/30410673
http://dx.doi.org/10.18632/oncotarget.26187

Ejemplares similares